Practice Pearls for Physicians Considering CAR T-cell Therapy for Patients with LBCL
Closing out this discussion of post-ASH 2022 perspectives, Matthew Lunning, DO, FACP, shares important clinical practice pearls for physicians considering CAR T-cell therapy for patients with LBCL.
Treatment Sequencing in LBCL: Clinical Trial and Real-World Data
Experts discuss the role of clinical and real-world data in informing treatment sequencing in patients with large B-cell lymphoma (LBCL) in the academic and community setting,
Additional Key Data Updates from ASH 2022 on Treatment of LBCL
Experts highlight additional data updates from the ASH 2022 annual meeting regarding the treatment of patients with LBCL.
Choosing the Appropriate CAR T-Cell Therapy in Patients with R/R DLBCL
Dr Lunning, DO, FACP, shares his impressions on the toxicity profile of axi-cel and liso-cel, and how he approaches treatment decision making for patients with relapsed-refractory (R/R) large B-cell lymphoma (LBCL).
CAR T-Cell Therapy as Second-Line Treatment in LBCL
Matthew Lunning, DO, FACP, discusses the role of CAR T-cell therapy in the second-line treatment of large B-cell lymphoma (LBCL).
Treatment Strategies for Patients with R/R LBCL
Experts provide their perspective on the treatment landscape for patients with relapsed-refractory (R/R) large B-cell lymphoma (LBCL).
CAR T-Cell Therapy in R/R LBCL: TRANSFORM, ZUMA-7, and PILOT Studies
In the context of CAR T-cell therapy, Manali Kamdar, MD, reviews TRANSFORM, ZUMA-7, and PILOT trials in the treatment of patients with relapsed-refractory (R/R) large B-cell lymphoma (LBCL).
Overview of Large B-Cell Lymphoma (LBCL)
Experts discuss Large B-Cell Lymphoma (LBCL) and treatment strategies for patients with LBCL.
Dr. Lunning on the Evolution of BTK Inhibitors in CLL
Matthew A. Lunning, DO, FACP, discusses the evolution of BTK inhibitors in chronic lymphocytic leukemia.
Role of Bispecifics and Future Promising Treatments in DLBCL
Shared excitement for bispecific antibodies and other promising novel therapies in the treatment of patients with DLBCL.
The Future of DLBCL Treatment
A look at exciting investigational agents and clinical trials for patients with relapsed/refractory diffuse large B-cell lymphoma.
Management and Work-up of Patients for Salvage Therapy
The panelists share their approach to the treatment and work-up of patients who require salvage therapy.
Strategies for Supportive Care and Monitoring in Patients Who Have Received CAR T-Cell Therapy
Experts in lymphoma take part in a discussion on supportive care for patients who receive CAR T-cell therapy.
A Closer Look at CAR T-Cell Therapy Clinical Trial Design
Subject matter experts in lymphoma reflect on chimeric antigen receptor T-cell therapy clinical trial design.
Clinical Trials Evaluating CAR T-Cell Therapies in Second-Line Treatment of Patients With DLBCL
Frederick Locke, MD, provides an in-depth look at data from 3 clinical trials investigating chimeric antigen receptor T-cell therapy in the second-line treatment of diffuse large B-cell lymphoma.
Therapeutic Sequencing and Bridging in DLBCL
Optimizing approaches to therapeutic sequencing in relapsed/refractory DLBCL.
Treating Patients Who Relapse or Progress on CAR T-Cell Therapy
Drs Nowakowski and Gordon discuss treatment options after disease relapse on CAR T-cell therapy.
A Closer Look at the Potential Impact of Bispecific Antibodies on the DLBCL Treatment Landscape
Physicians speculate on the potential impact of bispecific antibodies on the treatment landscape of DLBCL.
Comparing Real-World Evidence With Data From Clinical Trials
The panelists discuss the importance of using real-world evidence in addition to data from clinical trials to inform decision-making.
Tafasitamab plus Lenalidomide as a Treatment in Patients With R/R DLBCL
Oncologists discuss the efficacy and safety of a tafasitamab plus lenalidomide for relapsed/refractory DLBCL and share personal experiences relevant to its use.
Selecting Among Available Treatment Options for Patients With Relapsed/Refractory DLBCL
Caron Jacobson, MD, and Matthew Lunning, DO, FACP, assess the available treatment options for patients with R/R DLBCL.
Improving Outcomes in Patients With DLBCL
Drs Locke and Gordon explain how outcomes for patients with DLBCL have improved as treatments continue to evolve.
A Focus on Frontline Treatment in Patients With DLBCL
Experts in lymphoma discuss how they risk stratify patients and the currently available options for first-line diffuse large-b cell lymphoma treatment.
Dr. Lunning on the FDA Approval of Liso-cel in LBCL
Matthew A. Lunning, DO, FACP, discusses how the FDA approval of lisocabtagene maraleucel expands treatment options for patients with large B-cell lymphoma.
Ribociclib Plus Endocrine Therapy Improves PFS and OS in Elderly Patients With HR+/HER2– Breast Cancer
Dr Ganesan on the Use of ctDNA Assays For MRD Detection in Cancer Care
Dr Habib on Developments in Palliative Care For Patients With Cancer
Dr Boland on the Emergence of KRAS G12C Inhibitors in mCRC
2 Clarke Drive Cranbury, NJ 08512